Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.
1stDepartment of Cardiology and Angiology, Silesian Centre for Heart Diseases, Zabrze, Poland.
Int J Clin Pract. 2021 Jun;75(6):e14080. doi: 10.1111/ijcp.14080. Epub 2021 Feb 15.
Symptom-focused management is one of the cornerstones of optimal atrial fibrillation (AF) therapy.
To evaluate the use of rhythm control and rate control strategy. Second, to identify predictors of the use of amiodarone in patients with rhythm control and of the use of rhythm control strategy in patients with paroxysmal AF in the Balkans.
Prospective enrolment of consecutive patients from seven Balkan countries to the BALKAN-AF survey was performed.
Of 2712 enrolled patients, 2522 (93.0%) with complete data were included: 1622 (64.3%) patients were assigned to rate control strategy and 900 (35.7%) to rhythm control. Patients with rhythm control were younger, more often hospitalised for AF and with less comorbidities (all P < .05) than those with rate control. Symptom score [European Heart Rhythm Association (EHRA)] was not an independent predictor of a rhythm control strategy [odds ratio (OR) 0.99, 95% confidence interval (CI) 0.90-1.10, P = .945]. The most commonly chosen antiarrhythmic agents were amiodarone (49.7%), followed by propafenone (24.3%).
More than one-third of patients in the BALKAN-AF survey received a rhythm control strategy, and these patients tended to be younger with less comorbidities than those managed with rate control. EHRA symptom score is not significantly associated with rhythm control strategy. The most commonly used antiarrhythmic agents were amiodarone, followed by propafenone.
以症状为导向的治疗是优化心房颤动(AF)治疗的基石之一。
评估节律控制和心率控制策略的应用。其次,确定巴尔干地区节律控制患者中使用胺碘酮和阵发性 AF 患者中使用节律控制策略的预测因素。
前瞻性纳入来自七个巴尔干国家的连续患者参加 BALKAN-AF 调查。
在纳入的 2712 例患者中,有 2522 例(93.0%)完成了完整数据的纳入:1622 例(64.3%)患者被分配到心率控制策略,900 例(35.7%)被分配到节律控制策略。与心率控制组相比,节律控制组的患者年龄更小,因 AF 住院的频率更高,合并症更少(所有 P<.05)。症状评分[欧洲心律协会(EHRA)]不是节律控制策略的独立预测因素[比值比(OR)0.99,95%置信区间(CI)0.90-1.10,P=.945]。最常选择的抗心律失常药物是胺碘酮(49.7%),其次是普罗帕酮(24.3%)。
在 BALKAN-AF 调查中,超过三分之一的患者接受了节律控制策略,与接受心率控制的患者相比,这些患者的年龄更小,合并症更少。EHRA 症状评分与节律控制策略无显著相关性。最常使用的抗心律失常药物是胺碘酮,其次是普罗帕酮。